COR Therapeutics
Executive Summary
Phase II trials of COR's Integrelin agent for treatment of unstable angina have begun at Johns Hopkins Hospital and Francis Scott Key Medical Center, both in Baltimore. Phase I trials indicate that Integrelin "may act as an effective antithrombotic compound by inhibiting platelet aggregation, with minimal side effects and rapid reversibility," the South San Francisco-based R&D firm said Feb. 27 release.